- Home
- ICCM vs IGC Comparison
ICCM vs IGC Comparison
Compare ICCM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- IGC
- Stock Information
- Founded
- ICCM 2006
- IGC 2005
- Country
- ICCM Israel
- IGC United States
- Employees
- ICCM N/A
- IGC N/A
- Industry
- ICCM
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- IGC Health Care
- Exchange
- ICCM Nasdaq
- IGC Nasdaq
- Market Cap
- ICCM 55.8M
- IGC 20.2M
- IPO Year
- ICCM N/A
- IGC N/A
- Fundamental
- Price
- ICCM $1.01
- IGC $0.30
- Analyst Decision
- ICCM Strong Buy
- IGC Strong Buy
- Analyst Count
- ICCM 1
- IGC 2
- Target Price
- ICCM $2.50
- IGC $3.88
- AVG Volume (30 Days)
- ICCM 287.1K
- IGC 242.6K
- Earning Date
- ICCM 08-19-2025
- IGC 06-27-2025
- Dividend Yield
- ICCM N/A
- IGC N/A
- EPS Growth
- ICCM N/A
- IGC N/A
- EPS
- ICCM N/A
- IGC N/A
- Revenue
- ICCM $3,273,000.00
- IGC $1,271,000.00
- Revenue This Year
- ICCM $83.41
- IGC $15.26
- Revenue Next Year
- ICCM $185.02
- IGC $3.41
- P/E Ratio
- ICCM N/A
- IGC N/A
- Revenue Growth
- ICCM 0.34
- IGC N/A
- 52 Week Low
- ICCM $0.48
- IGC $0.25
- 52 Week High
- ICCM $1.66
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- ICCM 45.31
- IGC 44.68
- Support Level
- ICCM $0.81
- IGC $0.30
- Resistance Level
- ICCM $1.03
- IGC $0.32
- Average True Range (ATR)
- ICCM 0.06
- IGC 0.01
- MACD
- ICCM 0.01
- IGC -0.00
- Stochastic Oscillator
- ICCM 71.83
- IGC 12.50
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.